VBI Vaccines Inc. [VBIV] stock Resumed by Jefferies analyst, price target now $6

Related

VBI Vaccines Inc. [NASDAQ: VBIV] stock went on an upward path that rose over 8.87% on Wednesday, amounting to a one-week price decrease of less than -25.43%. The company report on June 7, 2022 that VBI Vaccines to Participate in the Jefferies Healthcare Conference.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022.

Over the last 12 months, VBIV stock dropped by -81.44%. The one-year VBI Vaccines Inc. stock forecast points to a potential upside of 89.06. The average equity rating for VBIV stock is currently 1.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $202.16 million, with 258.26 million shares outstanding and 204.57 million shares in the current float. Compared to the average trading volume of 2.09M shares, VBIV stock reached a trading volume of 4133687 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on VBI Vaccines Inc. [VBIV]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VBIV shares is $6.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VBIV stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for VBI Vaccines Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 29, 2021. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on February 25, 2021, representing the official price target for VBI Vaccines Inc. stock. Previously, the target price had yet another raise from $8 to $9, while Raymond James kept a Strong Buy rating on VBIV stock.

The Average True Range (ATR) for VBI Vaccines Inc. is set at 0.09, with the Price to Sales ratio for VBIV stock in the period of the last 12 months amounting to 404.32. The Price to Book ratio for the last quarter was 1.46.

VBIV Stock Performance Analysis:

VBI Vaccines Inc. [VBIV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -25.43. With this latest performance, VBIV shares dropped by -29.87% in over the last four-week period, additionally sinking by -67.44% over the last 6 months – not to mention a drop of -81.44% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VBIV stock in for the last two-week period is set at 34.64, with the RSI for the last a single of trading hit 33.69, and the three-weeks RSI is set at 35.93 for VBI Vaccines Inc. [VBIV]. The present Moving Average for the last 50 days of trading for this stock 1.1726, while it was recorded at 0.7558 for the last single week of trading, and 2.0853 for the last 200 days.

Insight into VBI Vaccines Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and VBI Vaccines Inc. [VBIV] shares currently have an operating margin of -10781.62 and a Gross Margin at -1897.62. VBI Vaccines Inc.’s Net Margin is presently recorded at -11054.36.

Return on Equity for this stock declined to -44.21, with Return on Assets sitting at -33.24.

VBI Vaccines Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.30.

VBI Vaccines Inc. [VBIV] Insider Position Details

There are presently around $77 million, or 45.50% of VBIV stock, in the hands of institutional investors. The top three institutional holders of VBIV stocks are: PERCEPTIVE ADVISORS LLC with ownership of 52,335,002, which is approximately 0% of the company’s market cap and around 0.52% of the total institutional ownership; STATE STREET CORP, holding 16,216,811 shares of the stock with an approximate value of $10.87 million in VBIV stocks shares; and BLACKROCK INC., currently with $8.86 million in VBIV stock with ownership of nearly -0.363% of the company’s market capitalization.

Positions in VBI Vaccines Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 62 institutional holders increased their position in VBI Vaccines Inc. [NASDAQ:VBIV] by around 8,187,068 shares. Additionally, 54 investors decreased positions by around 3,829,658 shares, while 32 investors held positions by with 103,592,395 shares. The mentioned changes placed institutional holdings at 115,609,121 shares, according to the latest SEC report filing. VBIV stock had 16 new institutional investments in for a total of 767,313 shares, while 16 institutional investors sold positions of 363,805 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]